Pharmaceuticals, Biotechnology and Life Sciences
Vectura Group confirmed on Thursday what its partner Hikma Pharmaceuticals said in its interim results statement about its abbreviated new drug application (ANDA) filing for a US generic version of Advair Diskus.
Vectura Group has reached a royalty cap on net sales of £9 million from selling GSK’s respiratory Ellipta products in 2016.
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
Vectura’s partner on the VR876 programme has achieved an important development milestone in Europe, which triggered a cash milestone payment of €5m (circa. £3.6m) to Vectura.